Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228502 | 1.00 | MEN1 (0.47) | MEN1KMT2AGPR119USP30POLB | |
| SCHEMBL5231976 | 0.90 | ATM (0.37) | MEN1KMT2A | |
| SCHEMBL5231969 | 0.90 | ATM (0.37) | MEN1KMT2A | |
| SCHEMBL5231752 | 0.90 | GPR119 (0.46) | MEN1KMT2AGPR119POLBTP53 | |
| SCHEMBL5231742 | 0.90 | GPR119 (0.46) | MEN1KMT2AGPR119POLBTP53 | |
| SCHEMBL5235195 | 0.87 | L3MBTL1 (0.35) | MEN1KMT2APOLB | |
| SCHEMBL5235207 | 0.87 | L3MBTL1 (0.35) | MEN1KMT2APOLB | |
| SCHEMBL5237029 | 0.85 | CACNA2D1 (0.43) | MEN1KMT2APOLB | |
| SCHEMBL5238433 | 0.85 | CACNA2D1 (0.43) | MEN1KMT2APOLB | |
| SCHEMBL5233487 | 0.84 | ALDH1A1 (0.38) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | MEN1 4820/4885KMT2A 4445/4885GPR119 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.